This person is a member of Sanger Institute Alumni.

Chris Kirton has a background in molecular immunology and biopharmaceutical drug development, mainly antibodies and vaccines. Prior to joining the Sanger Institute Chris was a post-doc in the Division of Immunology at Cambridge University where he developed a monoclonal antibody against the inflammatory mediator VAP-1 and later became Head of the Cell Biology and Biopharmaceutical areas at ENVIGO, a global CRO.


My publications

Loading publications...